The evolution of gene therapy in X-linked severe combined immunodeficiency

Annals of Allergy, Asthma and Immunology

Volumn 102, Issue 5, 2009, Pages 357-363

  Rans, Tonya S ^a   England, Ronald ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE RECEPTOR GAMMA CHAIN; IMMUNOGLOBULIN; RECEPTOR SUBUNIT; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL CULTURE; CELLULAR IMMUNITY; CINAHL; CLINICAL TRIAL; DATA BASE; EX VIVO GENE TRANSFER; GENE INSERTION; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA; LYMPHOCYTE FUNCTION; MEDLINE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

EID: 66249113524     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60504-2     Document Type: Review

References (54)

1. Noguchi M, Yi H, Rosenblart HM, et al. Interleukin-2 receptor-chain mutation results in X-linked severe combined immunodeficiency in humans Cell. 1993;73:147-157.
2. Puck JM, Deschenes SM, Porter JC, et al. The interleukin-2 receptor-chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, XSCID1. Hum Mol Genet. 1992;2:1099 -1104.
3. Sugamura K, Asao H, Kondo M, et al. The common--chain for multiple cytokine receptors Adv Immunol. 1995;59:225-277.
4. Fischer A, Hacein-Bey S, Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol. 2002;2:615- 624.
5. Di Santo JP, Kuhn R, Muller W. Common cytokine receptor gamma chain (gamma c)-dependent cytokines: understanding in vivo functions by gene targeting. Immunol Rev. 1995;148:19 -34.
6. X-linked SCID mutation database (IL2RGbase): database of mutations causing human X-linked SCID. National Human Genome Research Institute Web site. http://research.nhgri.nih.gov/scid/IL2RGbase.shtml. Accessed June 20, 2008.
7. Amos DB, Bach FH. Phenotypic expressions of the major histocompatibility locus in man (HL-A): leukocyte antigens and mixed leukocyte culture reactivity, J Exp Med. 1968;128:623- 637.
8. Smogorzewska EM, Brooks J, Annett G, et al. T cell depleted haploidentical bone marrow transplantation for the treatment of children with severe combined immunodeficiency. Arch Immunol Ther Exp (Warsz). 2000;48:111-118.
9. Antoine C, Suller S, Cant A, et al. Long-term survival and transplantation of hematopoietic stem cells for immunodeficiencies: report of the European experience 1968-1999l. Lancet. 2003;361:553-556.
10. Tomaske M, Bosk A, Eyrich M, et al. Risks of mortality in children admitted to the paediatric intensive care unit after haematopoietic stem cell transplantation. Br J Haematol. 2003;121:886-891.
11. Buckley RH. Advances in the understanding and treatment of human severe combined immunodeficiency, Immunol Res. 2001;22:237-251.
12. Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2: 1366-1369.
13. Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell- depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 1998;91:3646 -3653.
14. Buckley RH, Schiff SE, Schiff, RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508 -516.
15. Clement-De Boers A, Oostdijk W, Van Weel-Sipman MH, Van den Broeck J, Wit JM, Vossen JM. Final height and hormonal function after bone marrow transplantation in children. J Pediatr. 1996;129:544 -550.
16. Otsu M, Candotti F. Gene therapy in infants with severe combined immunodeficiency. Biodrugs. 2002;16:229 -239.
17. Bertrand Y, Ladais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HAL non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency J Pediatr. 1999;134:740-748.
18. Blazar BR, Taylor PA, McElmurry R, et al. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via in utero postnatal transfer. Blood. 1998;92:3949-3959.
19. Chinen J, Puck JM. Successes and risks of gene therapy in primary immunodeficiencies. J Allergy Clin Immunol. 2004;113:595- 603.
20. Brenner S, Malech HL. Current developments in the design of oncoretrovirus and lentivirus vector systems for hematopoietic cell gene therapy. Biochim Biophys Acta. 2003;1640:1-24.
21. Patel DD, Gooding ME, Parrott RE, et al. Thymic function after hematopoieticstem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 2000;342:1325-1332.
22. Nathwani AC, Benjamin R, Nienhuis AW, Davidoff AM. Current status and prospects for gene therapy. Vox Sang. 2004;87:73-81.
23. Miller AD. Retroviral vectors. Curr Top Microbiol Immunol. 1992;158: 1-24.
24. Russell SJ, Peng KW. Primer on medical genomics, part X: genetherapy. Mayo Clin Proc. 2003;78:1370-1383.
25. Richter J. Gene transfer to hematopoietic cells: the clinical experience. Eur J Haematol. 1997;59:67-75.
26. Sadelain M, Frassoni F, Riviere I. Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. Curr OpinHematol. 2000;7:364 -377.
27. Cavazzana-Calvo M, Hacein-Bey S, de Saint Baseile G, et al. Genetherapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.
28. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy N Engl J Med. 2002;346:1185-1193.
29. Cornetta K, Srour EF, Moore A, et al. Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. HumGene Ther. 1996;6:1323-1329.
30. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors: design, biosafety, and production. Gene Ther. 2005;12:1089 -1098.
31. Hacein-Bey S, Gross F, Nusbaum P, et al. Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells. Hum Gene Ther. 2001;12:291-301.
32. Hanenberg H, Xiao XL, Dilloo D, et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 1996;2:876-882.
33. Hanenberg H, Hashino K, Konishi H, et al. Optimization of fibronectinassisted retroviral gene transfer into human CD34-hematopoietic cells. Hum Gene Ther. 1997;8:2193-2206.
34. Heim DA, Dunbar CE. Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency. Immunl Rev. 2000;178:29-38.
35. Kohn DB, Sadelain M, Dunbar C, et al; American Society of Gene Therapy (ASGT). American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther. 2003;8:180 -187.
36. Donahue RE, Kessler WE, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med. 1992;176:1125-1135.
37. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Role of interleukin-2 (IL-2), IL-7, IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c tranduced severe combined immunodeficiency X1 bone marrow cells. Blood. 1996;88:3901-3909.
38. Hacein-Bey S, Basile GD, Lemerle J, et al. γc gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from-c (-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood. 1998;92:4090-4097.
39. DiSanto JP, Muller W, Guy-Grand D, et al. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor-chain. Proc Natl Acad Sci U S A. 1995;92:277-281.
40. Stephan V, Wahn V, Le Deist F, et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 1996;335:1563-1567.
41. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCIDX1. Science. 2003;302:415- 419.
42. Rabbitts TH, Bucher K, Chung G, et al. The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development. Cancer Res. 1999;59:1794s-1798s.
43. Cole A. Child in gene therapy programme develops leukaemia. BMJ. 2008;336:13.
44. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181-2187.
45. Stem cell gene therapy to treat X-linked severe combined immunodeficiency (XSCID). Clinicaltrials.gov Web site. http://www.clinical trials.gov/ct2/show/ NCT00028236?term-gene-therapy&rank-22. Accessed June 22, 2008.
46. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2004;350:913-922.
47. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80:148-158.
48. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003; 300:1749-1751.
49. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science. 2004;303:333.
50. Wang GP, Garrigue A, Ciuffi A, et al. DNA bar coding and pyrosequencing to analyze adverse events of therapeutic gene transfer. Nucleic Acids Res. 2008;36:e49.
51. Emery DW, Yannaki E, Tubb J, et al. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl AcadSci U S A. 2000;97:9150-9155.
52. Burgess-Beusse B, Farrell C, Gaszner M, et al. The insulation of genes from external enhances and silencing chromatin. Proc Natl Acad Sci U S A. 2002;99(suppl 4):16433-16437.
53. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Eng J Med. 2009; 360:447- 458.
54. Kohn DB, Candotti F. Gene therapy fulfilling its promise. N Eng J Med. 2009;360:518-521.